Bionomics Investor Presentation Deck

BNC210 is Well-Positioned in Post-Traumatic Stress Disorder restore ++++ ✓ Anti-depressant and anti-anxiety trends seen at earlier time points ✓ Safety profile generally well tolerated Did not meet primary endpoint*; lower than expected exposure of liquid suspension formulation Bionomics BU Pharmacometric analysis of Phase 2 PTSD data ✓ Predicted significant efficacy potential with adequate drug exposure achieved *Primary endpoint of CAPS-5 total symptom severity score at 12 weeks HE neee Ue e e New tablet formulation overcomes food effect of suspension formulation Achieved exposure target predicted from pharmacometric analysis ✓ Extended IP coverage FDA 晶 Type C meeting with FDA ✓ FDA granted Fast Track designation in PTSD ATTUNE Study Phase 2b ATTUNE trial started in July 2021 ✓ Topline data expected 1H 2023 17

View entire presentation